Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®
Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” Program
Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor
Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium
Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society
Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24
Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
Artelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.